Document |
Document Title |
WO/2024/002934A1 |
The present invention relates to 8-heterocyclic-3-(phenylsulfonyl)-[1,2,3] triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (...
|
WO/2024/002373A1 |
The present invention relates to a substituted pyrimidine-fused ring inhibitor, a method for preparing same, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclos...
|
WO/2023/246914A1 |
Disclosed are a heterocyclic substituted pyrimidopyran compound and use thereof. In particular, disclosed is a compound represented by formula (VII) and a pharmaceutically acceptable salt thereof.
|
WO/2023/246371A1 |
The present application discloses a small molecule compound having a pyrimidothiophene structure, and a use thereof. By means of inhibiting activity of the cyclin-dependent kinase (CDK) family, the small molecule compound can block the c...
|
WO/2023/246903A1 |
The present invention provides a selenium-containing heterocyclic compound with a structure represented by formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof or a deuterated ...
|
WO/2023/250430A1 |
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same
|
WO/2023/246837A1 |
The present invention relates to a class of compounds having a pyrimido-six-membered ring structure, pharmaceutical compositions comprising same, and use thereof. The compounds have a structure represented by formula (I) below. Experimen...
|
WO/2023/244639A1 |
The present disclosure relates to methods of treating cancer in a subject, comprising analyzing one or more biological sample(s) for the presence of a first genetic marker and administering an EGFR inhibitor to the subject if the presenc...
|
WO/2023/241552A1 |
The present disclosure provides salt and/or crystal form for compounds, especially for compounds as casein kinase inhibitors.
|
WO/2023/241608A1 |
The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.
|
WO/2023/241618A1 |
Disclosed are a series of aminopyrimidine compounds and use thereof, and specifically disclosed are a compound represented by formula (XI), a stereoisomer thereof and a pharmaceutically acceptable salt thereof, and use thereof.
|
WO/2023/244806A1 |
Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI/SNF-related matrix-assoc...
|
WO/2023/240920A1 |
The present invention relates to a sulfur-containing artemisinin analogue dimer, and a preparation method therefor and the use thereof, which belong to the technical field of pharmaceutical chemistry. The sulfur-containing artemisinin an...
|
WO/2023/240038A1 |
This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)),...
|
WO/2023/238930A1 |
Provided are novel compounds which are analogues to be removed from APIs and formulations. Also provided are standard products of analogues to be used in controlling the qualities of medicines. Analogue 1: 3-ethyl-4-\{4-[4-(1-methyl-1H-p...
|
WO/2023/240189A1 |
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
|
WO/2023/240188A1 |
The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
|
WO/2023/238919A1 |
Provided is an anticancer agent capable of efficaciously acting on a Ras mutated cancer. The present invention provides a hybrid type compound, in which trametinib is linked to an Akt inhibitor via a linker, or a salt thereof.
|
WO/2023/230968A1 |
Provided are an SHP2 inhibitor, and a crystal form thereof, a preparation method therefor, and a use thereof. Provided are a crystal form B of a compound as shown in formula (I), a compound as shown in formula (II) and a crystal form A t...
|
WO/2023/232776A1 |
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
WO/2023/232135A1 |
Disclosed are a compound as represented by formula I; a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same; and the use thereof as a PDE4B inhibitor in the preparation of a drug fo...
|
WO/2023/233130A1 |
The present invention relates to compounds of formula I shown below: wherein R1, X2, X3, X4, X5, X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compo...
|
WO/2022/221227A9 |
Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing canc...
|
WO/2023/227139A1 |
The invention relates to a novel fused pyrimidine compound as shown in general formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and preparation methods and uses therefor. The meanings of R1, R2,...
|
WO/2023/226630A1 |
Provided is a polymorph of a cycloalkyl and heterocycloalkyl inhibitor or a salt thereof. Specifically, the present invention relates to a polymorph of (S)-2-(4-(7-(8-chloro-7-fluoronaphthalen-1-yl)-2-(1-((dimeth
ylamino)methyl)cycloprop...
|
WO/2023/227052A1 |
Disclosed herein are a compound represented by formula (II) or a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated form thereof, or a pharmaceutical composition comprising same, and use thereof as ...
|
WO/2023/230190A1 |
Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.
|
WO/2023/223925A1 |
The present invention provides: a compound that, while being a curable resin, can easily achieve, when being formed into a cured product, the abilities to be repaired, to be easily disassembled, and to be remolded; and a curable resin co...
|
WO/2023/225302A1 |
Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.
|
WO/2023/225244A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
|
WO/2023/221797A1 |
The present invention relates to a heterocyclic compound, a pharmaceutical composition comprising same, and a preparation method for the heterocyclic compound, and further relates to a use of the compound in the preparation of a drug for...
|
WO/2023/217230A1 |
The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
|
WO/2023/215991A1 |
Provided are compounds and method for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat disease, including, but not limited to, cancer. In certain emb...
|
WO/2023/220640A1 |
Provided herein are CDK protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CDK-me...
|
WO/2023/220098A1 |
The present disclosure is directed to methods of treating colorectal cancer in a subject in need thereof with a menin-MLL inhibitor, including Compound A. Methods for dosing Compound A for various indications are also provided by the pre...
|
WO/2023/220421A1 |
Provided are small molecule inhibitors of the KRAS (G12D) mutant oncoprotein having the structural formula: R00F2C-L-R0 and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related con...
|
WO/2022/213204A9 |
The use of inhibitors of tyrosine and threonine- specific cdc2-inhibitory kinase (Mytl) in the treatment of cancer is disclosed. In preferred embodiments, the Mytl inhibitor is a carboxamide pyrrolopyrazine or carboxamide pyrrolopyridine...
|
WO/2023/220219A1 |
The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
|
WO/2023/215494A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
WO/2023/215906A1 |
Provided herein are KRAS G12D proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS G12D PROTACs, and methods of making and using the KRAS G12D PROTACs, e.g., to promote degradation of KRAS G12D and/or treat KRAS G12...
|
WO/2023/215802A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
|
WO/2023/213882A1 |
Compounds of formula (I) processes for their production and their use as pharmaceuticals.
|
WO/2023/215801A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same in the treatment of cancer or for inhibiting cell growth. The compounds and methods have a range of utilities as thera...
|
WO/2023/212239A1 |
Described herein are compounds of formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
|
WO/2023/212535A1 |
The present invention provides compounds of the formula (I):, or a pharmaceutically acceptable salt thereof, wherein A, X1, X2, X3, Y, Z, Z1, Z2, R2 and R6 are as defined herein, for use in the treatment of cancer and a method of treatin...
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
WO/2023/212071A1 |
Provided here is a method of treating a cancer in a subject in need thereof, comprising administering to said subject a combination comprising: (i) about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg,...
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
WO/2023/207944A1 |
The present invention relates to a crystal form of an FGFR4 inhibitor and use thereof. The present invention provides a compound of formula B in crystalline form. The compound of formula B of the present invention has excellent FGFR4 kin...
|
WO/2023/208127A1 |
Disclosed are a series of heteroaryl-substituted bicyclic compounds and use thereof, and particularly, disclosed are a compound represented by formula (P), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
|